That's very interesting. I did a quick check and it appears that in the Ven/Gilt and Ven/Quiz combinations VEN is used in the 400mg+range. If we see efficacy with Ven at 50 or 100mg with TUSP I would expect a significant reduction in myelo-suppression. There must be a reason APTO is testing with this significantly lower Ven dose. Naval Daver is in the thick of all this.
I listened to BDTX presentation. Nice story. May pay a little more attention to it as they generate data. I haven't been too focused on EGFR lately, but I am interested in the RAS program as it compares to some other RAS pathway strategies. I currently have quite a bit of VSTM and am watching IKNA. Both have RAS/RAF clamps in development.
News 
Market Data 
Discover 
